Because Nurr1 overexpression can protect DAnergic neurons from α-synuclein [120], combining AAV–Nurr1 with GDNF or NRTN in the midbrain might improve the outcomes of clinical trials and may prove to be a desirable alternative therapy for PD. This evidence concerns the gene NR4A2 and Parkinson disease.